Phase II study of bortezomib dexamethasone and high-dose melphalan in patients with relapse after high-dose melphalan with autologous stem cell support.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2015
At a glance
- Drugs Bortezomib; Dexamethasone; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2010 Planned end date changed from 1 Jul 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 17 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.